All News

Demcizumab, a monoclonal antibody that targets the Notch signaling pathway, has been awarded an orphan drug status by the FDA in the treatment of pancreatic cancer.

Three out of four physicians believe that fellow doctors prescribe an unnecessary test or procedure at least once a week, a survey released Thursday finds.

The Centers for Medicare & Medicaid Services (CMS) proposed a rule this week that would reduce payments for hospital readmissions and hospital-acquired conditions in 2015.

The Federation of State Medical Boards approved a model telehealth policy this weekend that's made some providers of these services happy and others, well, not so much, because of its emphasis on using video rather than audio technology for a first patient visit.

In this study, the authors engineered BMP4-secreting mesenchymal stem cells to study their effect on a glioblastoma mouse model.

Value-based insurance design (V-BID) encourages providers to deliver higher quality services at lower out-of-pocket costs for patients, and it is increasingly gaining bipartisan support in Congress.

The Centers for Medicare & Medicaid Services late Wednesday issued a proposed rule for 2015 that reduces payment for readmissions and hospital-acquired conditions, but provides no changes to the controversial two-midnight rule.

An advisory panel to the CMS voted against recommending an annual low-dose CT scan for high-risk individuals citing no benefit over the harm of false-positives.

To better manage population health, some providers now invest in preventive technology and patient outreach as part of an initiative to eventually create "patient-centered medical neighborhoods," Becker's Hospital Review reports.

The White House sought to quash any fear that Obamacare is reversing downward trends in health spending as very preliminary estimates for U.S. economic growth in the first months of 2014 suggested spending on healthcare is rebounding sharply.

Validation studies presented at the annual meeting of the American Association for Thoracic Surgery push availability of the DecisionDx-Mesothelioma molecular test through an early access program.

Following a FDA advisory earlier in the month of an increased risk of cancer spread, Johnson and Johnson suspended the global sale of a device used in fibroid surgery.

A company in Baltimore is personalizing cancer therapy by developing patient-derived tumor xenografts in mice to identify the most effective drugs for the patient.

By adopting ASCO's electronic data-sharing guide for it's breast cancer treatment, Athena hopes to improve coordination of care, registration submission and research.

The early detection of rheumatoid arthritis (RA) in patients is important to reduce the risk for negative long-term outcomes.

Medicaid managed-care plans are looking to state officials for help as they face massive outlays for the new hepatitis C drug Sovaldi, which costs $84,000 for a 12-week course of treatment.

Left as-is, current exchange formuarly and network search technology has the potential for a lot of consumer dissatisfaction and backlash.

Hundreds of thousands of Medicaid recipients in Illinois are being shifted into some kind of managed care this year as part of a sweeping overhaul intended to fix a program widely acknowledged to be broken.

Sativex,a cannabinoid developed together by GW Pharmaceuticals and Otsuka, receives FDA's Fast Track status for advanced cancer pain.

3D printing of tumors could provide a more physiological environment to boost cancer drug discovery and development.

The US FDA today approved Zykadia (ceritinib), a ALK tyrosine kinase inhibitor developed by Novartis, for treatment of late-stage NSCLC.

Most people want to take medications as prescribed, even if they sometimes need a little help remembering. For them, an automated system that monitors drug taking and provides feedback after the fact may be more useful than one that nags people when it is time to take a pill, researchers at Carnegie Mellon University say.

A federally funded effort to identify high-risk patients and coordinate their care is delivering modest savings, but significant cost reductions may come only after broader payment reforms take hold.

Despite a growing number of people becoming insured in 2014, attitudes have not shifted about the Affordable Care Act.

A collaboration between Aetna, MOASC Contracting Network and Cardinal Health Specialty Solutions aims to improve quality and cost of cancer care in California.

Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. today announced results from the Phase III SYNERGY trial, a randomized, open-label, two-arm study comparing the combination of custirsen and standard first-line docetaxel/prednisone therapy to docetaxel/prednisone alone in men with metastatic castrate-resistant prostate cancer (CRPC)

Among surprises from a new study on U.S. health spending is the realization: Whether insured or not, young adults spent about the same on out-of-pocket health expenditures throughout the year.

As provider reimbursement begins to move toward models that favor quality over quantity, CEO compensation may be following the same path-with CEO pay determined more by quality measures than strictly by financial gains.

Quality-of-care performance means more to CEO paychecks at some for-profit hospital companies than at others.